Adeno-Associated Virus-Mediated Rhodopsin Replacement Provides Therapeutic Benefit in Mice with a Targeted Disruption of the Rhodopsin Gene
- 1 March 2010
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 21 (3) , 311-323
Abstract
The rhodopsin gene (RHO) encodes a highly expressed G protein-coupled receptor that is central to visual transduction in rod photoreceptors. A suite of recombinant 2/5 adeno-associated viral (AAV) RHO replacement vectors has been generated in an attempt to recapitulate endogenous rhodopsin levels from exogenously delivered AAV vectors in the retina of mice with a targeted disruption in the rhodopsin gene (Rho(-/-) mice). Approximately 40% of wild-type mouse rhodopsin mRNA levels (RNA taken from whole retinas) was achieved in vivo in AAV-RHO-injected eyes, representing approximately 50-fold increases in expression compared with the initial vector. The main focus of this study was to test whether expression of AAV-RHO replacement in Rho(-/-) mice provided therapeutic benefit, which to date had not been achieved. Rho(-/-) mice neither elaborate rod outer segments nor have rod-derived electroretinograms (ERGs). Our results indicate for the first time in this model that subretinal AAV-RHO delivery leads not only to RHO immunolabeling but the generation of rod outer segments as evaluated by light and transmission electron microscopy. Improved histology was accompanied by rod photoreceptor activity as assessed by ERG for at least 12 weeks postinjection. The most efficient AAV-RHO constructs presented in this study provide sufficient levels of RHO to be of therapeutic benefit in Rho(-/-) mice and therefore represent important steps toward generating potent AAV-RHO replacement genes for gene therapy in RHO-linked human retinopathies.Keywords
This publication has 51 references indexed in Scilit:
- Improved Retinal Function in a Mouse Model of Dominant Retinitis Pigmentosa Following AAV-delivered Gene TherapyMolecular Therapy, 2009
- The outer segment serves as a default destination for the trafficking of membrane proteins in photoreceptorsJournal of Cell Biology, 2008
- Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kineticsProceedings of the National Academy of Sciences, 2008
- Effect of Gene Therapy on Visual Function in Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in miceJournal of Clinical Investigation, 2008
- A role for rhodopsin in a signal transduction cascade that regulates membrane trafficking and photoreceptor polarityVision Research, 2006
- Retinitis pigmentosa, pigmentary retinopathies, and neurologic diseasesCurrent Neurology and Neuroscience Reports, 2006
- Towards mutation-independent silencing of genes involved in retinal degeneration by RNA interferenceGene Therapy, 2005
- Gene therapy restores vision in a canine model of childhood blindnessNature Genetics, 2001
- A point mutation of the rhodopsin gene in one form of retinitis pigmentosaNature, 1990